Selecting a Contract Development and Manufacturing Organization (CDMO) is one of the most important decisions a pharmaceutical company will make during the life of a product.
Whether a program is entering development, preparing for technology transfer, or moving into commercial manufacturing, the chosen partner will influence timelines, budgets, regulatory readiness, product quality, and ultimately the success of the program itself.
Many sponsor organizations evaluate potential CDMOs using only the most obvious criteria. They compare equipment, manufacturing capacity, regulatory history, and pricing. While all of those considerations are certainly important, they rarely provide the complete picture.
The strongest pharmaceutical outsourcing relationships are built on far more than technical capability alone.
Asking the right questions early can reveal how a CDMO truly operates long before contracts are signed.
-
1. How Much Experience Do You Actually Have With Products Like Mine?
Many CDMOs promote broad manufacturing capabilities across numerous dosage forms. While that breadth may appear impressive, sponsors should look beyond general statements and explore actual experience.
If your product is a topical cream, nasal spray, oral liquid, or another specialized dosage form, ask how many similar technology transfers the organization has completed. Ask how many comparable products they have developed, manufactured, filed, and successfully commercialized. Request examples of programs that required similar technical expertise.
A company that manufactures a particular dosage form every day brings a different level of confidence than one that performs that work only occasionally.
Experience is measured not by what a CDMO says it can manufacture, but by what it has consistently demonstrated over time.
-
2. Who Will Be Involved Before the Proposal Is Even Written?
One of the earliest indicators of a successful CDMO relationship is who participates in the initial technical discussions.
If conversations involve only business development personnel, sponsors may receive optimistic answers before the organization’s technical experts have evaluated the program. That increases the likelihood of revised timelines, unexpected costs, or manufacturing limitations being discovered later.
A stronger approach brings pharmaceutical development, commercial manufacturing, analytical sciences, quality, operations, engineering, and project management into the conversation early. Those multidisciplinary discussions help establish realistic expectations while identifying potential challenges before commitments are made.
The quotation should reflect technical understanding, not assumptions.
-
3. How Will You Manage Communication Throughout My Program?
Communication is often treated as a soft skill within pharmaceutical outsourcing.
In reality, it is one of the most important operational capabilities a CDMO can possess.
Ask how project updates are communicated. Determine whether milestones can be tracked in real time. Understand how documentation is shared and how questions are escalated. Most importantly, ask how unexpected issues are handled.
No technology transfer proceeds without challenges. The real measure of a manufacturing partner is not whether obstacles occur, but how quickly they communicate those challenges and present practical solutions.
Transparency should be part of the process from the very first day.
-
4. How Do You Determine Whether My Timeline Is Realistic?
Every pharmaceutical company wants to accelerate development.
Every CDMO wants to win new business.
Those two objectives can sometimes create unrealistic expectations.
Sponsors should ask exactly how proposed timelines are developed. Are raw material lead times included? Have packaging components been evaluated? Has manufacturing capacity been confirmed? Have analytical testing requirements been incorporated? Have regulatory considerations been accounted for?
A realistic timeline may occasionally be longer than a sponsor hopes to hear, but it is far more valuable than an aggressive schedule that ultimately cannot be achieved.
Reliable planning builds confidence.
False optimism creates disappointment.
-
5. How Do Your Internal Teams Work Together?
Many project challenges originate long before sponsors ever become aware of them.
The question is whether the CDMO identifies those issues internally before they affect the customer.
Ask how pharmaceutical development collaborates with operations. Determine how quality assurance participates during project planning. Understand when environmental health and safety, analytical sciences, engineering, regulatory affairs, and supply chain become involved.
Organizations that operate collaboratively tend to identify risks early because every department contributes its expertise before critical decisions are made.
Companies that function in isolated departments often discover problems after commitments have already been made.
Internal communication frequently predicts external performance.
-
6. What Happens If Key Members of My Project Team Leave?
Technology transfers and commercial manufacturing programs often extend across many months or even years.
During that time, staffing changes are inevitable.
Sponsors should understand how institutional knowledge is preserved. Is there a backup project manager? Are customer preferences documented? Can another team member immediately assume responsibility without disrupting progress? How is project history maintained?
These questions may seem secondary during the excitement of a new program, but they become critically important when continuity is needed.
Strong organizations build redundancy into their project management structure because successful programs should never depend entirely on one individual.
-
7. How Will You Tell Me When Something Goes Wrong?
Perhaps the most revealing question of all has nothing to do with manufacturing equipment.
It concerns trust.
Every experienced pharmaceutical professional understands that unexpected challenges occasionally occur. A batch may require additional investigation. Materials may arrive late. Process parameters may need adjustment. Analytical results may warrant further evaluation. Those situations are not unusual. What matters is how the CDMO responds.
Ask how deviations are communicated. Ask who contacts the sponsor. Ask whether recommendations accompany the problem. Ask how quickly discussions take place once issues are identified.
The strongest pharmaceutical partnerships are built on honest communication, especially during difficult moments.
Good news should travel quickly; and challenges should travel even faster.
Why CPL Encourages These Questions
At CPL, these conversations are welcomed because they reflect the same philosophy that guides every customer relationship.
Technical experts become involved before proposals are finalized. Cross-functional teams evaluate opportunities collaboratively to ensure manufacturing strategies, timelines, equipment compatibility, analytical requirements, quality considerations, and project scope and costs are fully understood from the outset.
Throughout development and commercial manufacturing, structured project management systems support transparent communication, milestone visibility, and continuity across programs. Every commercial project includes backup personnel to preserve institutional knowledge and ensure sponsors continue receiving consistent support throughout the life of the relationship.
Most importantly, CPL believes successful pharmaceutical outsourcing depends upon strategic partnership rather than transactional manufacturing. Honest conversations occur early. Expectations are documented clearly. Challenges are communicated promptly, accompanied by thoughtful recommendations and practical solutions.
That commitment helps reduce risk while building the confidence sponsors need throughout technology transfer and commercial manufacturing.
Choosing a CDMO Is About More Than Manufacturing
Technical capabilities will always matter. Regulatory expertise will always matter. Commercial manufacturing capacity will always matter. But the pharmaceutical companies that consistently build successful outsourcing relationships understand that those qualities represent only part of the evaluation.
The right CDMO demonstrates technical excellence, operational discipline, transparent communication, collaborative culture, and a genuine commitment to helping sponsors succeed.
By asking these seven questions before selecting a manufacturing partner, pharmaceutical companies gain far greater insight into how a relationship will function after the contract is signed.
Because the best CDMO relationships are not built on promises. They are built on preparation, transparency, and trust from the very beginning.